Acurx Pharmaceuticals, Inc.
ACXP
$0.4791
-$0.0872-15.40%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 7.43M | 8.70M | 9.91M | 10.06M | 9.47M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 11.87M | 14.10M | 16.44M | 16.73M | 16.05M |
Operating Income | -11.87M | -14.10M | -16.44M | -16.73M | -16.05M |
Income Before Tax | -11.87M | -14.10M | -16.44M | -16.73M | -16.05M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -11.87 | -14.10 | -16.44 | -16.73 | -16.05 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -11.87M | -14.10M | -16.44M | -16.73M | -16.05M |
EBIT | -11.87M | -14.10M | -16.44M | -16.73M | -16.05M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.70 | -0.88 | -1.09 | -1.15 | -1.17 |
Normalized Basic EPS | -0.44 | -0.55 | -0.68 | -0.72 | -0.73 |
EPS Diluted | -0.70 | -0.88 | -1.09 | -1.15 | -1.17 |
Normalized Diluted EPS | -0.44 | -0.55 | -0.68 | -0.72 | -0.73 |
Average Basic Shares Outstanding | 69.16M | 64.59M | 61.50M | 58.14M | 54.50M |
Average Diluted Shares Outstanding | 69.16M | 64.59M | 61.50M | 58.14M | 54.50M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |